Why Is ARS Pharmaceuticals (SPRY) Stock Down -10.16% Today?
Key Takeaways
- Shares of SPRY fell 10.16% to $5.48 in Friday trading, down $0.62 from the prior close of $6.10.
- The primary catalyst was a second-quarter earnings report that missed analyst expectations on the bottom line despite stronger-than-expected revenue.
- Secondary pressures included softer gross margin, elevated operating expenses, and a delayed clinical data readout for the company's urticaria program.
- The move was company-specific rather than sector-driven, with the stock's decline reflecting investor reaction to the earnings print and guidance details.
- Traders are watching payer and formulary decisions, second-half expense reductions, and legal overhangs as the next potential catalysts.
Opening Summary
ARS Pharmaceuticals, Inc. (SPRY) is a San Diego-based biopharmaceutical company commercializing neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. In Friday's session, shares of SPRY fell 10.16% to $5.48, after closing the previous session at $6.10. The decline followed the company's second-quarter earnings release, which showed a wider-than-expected net loss per share even as revenue surpassed Wall Street forecasts.
Q2 Earnings Miss Overshadows Revenue Growth
The stock's sell-off was driven by a mixed second-quarter report. ARS Pharmaceuticals posted a net loss of $0.63 per share, wider than the $0.50 loss analysts had projected. Revenue came in at $33.66 million, above the $31.54 million consensus, and total U.S. net product revenue for neffy reached $26.2 million. The company also highlighted a doubling of its total U.S. market share to 5% year over year, with share within its field-targeted provider universe rising to 8%.
Despite that commercial progress, the earnings miss dominated the market reaction. Investors focused on the bottom-line shortfall and on signs that the company is still spending heavily to drive adoption of neffy. Total operating expenses were $95.1 million for the quarter, including $77.6 million in SG&A, reflecting costs tied to an earlier broad direct-to-consumer marketing strategy that the company is now shifting away from.
Margin, Spending and Pipeline Timing Add Pressure
Beyond the headline EPS miss, several details in the report reinforced the negative market reaction. Gross margin came in at about 62%, below prior projections, partly due to reserves for short-dated product and manufacturing inefficiencies as production scaled. Management also indicated that interim Phase 2b data for the chronic spontaneous urticaria program has been delayed to the first quarter of 2027, pushing back a potential pipeline milestone.
The company said it expects aggregate SG&A and R&D expenses in the second half of 2026 to be between $114 million and $126 million, including stock-based compensation, with cash-based SG&A and R&D expenses in the range of $100 million to $110 million. Management framed the updated expense outlook as a move toward financial discipline and reiterated a path to cash flow breakeven by the end of 2027, but the near-term cost levels and delayed pipeline catalyst contributed to the stock's decline.
Market Context and Trading Activity
The drop in SPRY appeared to be an idiosyncratic, earnings-driven move rather than part of a broader biotech sell-off. The stock gapped lower at the open, consistent with pre-market weakness, and remained under pressure during early trading. The decline pushed shares well below their 50-day and 200-day simple moving averages and closer to the lower end of the stock's 52-week range, reflecting the market's reassessment of near-term execution risks.
Trading activity reflected elevated attention following the earnings release and conference call. With the stock already down sharply over the trailing three- and twelve-month periods, Friday's move added to existing technical pressure and underscored investor sensitivity to spending levels, payer coverage timing, and pipeline updates.
What Comes Next for ARS Pharmaceuticals
Investors will be watching whether the company's shift toward targeted provider engagement and reduced direct-to-consumer spending translates into improved operating efficiency and sustained market-share gains for neffy. Payer and formulary decisions remain a key swing factor, since broader commercial access is central to the product's growth trajectory.
Other areas of focus include the timing of the delayed urticaria data readout, the pace of gross-margin improvement into 2027, and any developments in the securities litigation the company faces over prior coverage-related disclosures. While the company has reiterated a goal of reaching cash flow breakeven by the end of 2027, execution risks around spending discipline, adoption rates, and pipeline milestones remain central to the stock's near-term direction.
Trending AI Robots
Tickeron's Trending AI Robots page highlights AI-powered trading bots that are currently performing strongly under live market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to monitor automated approaches across different market environments. Explore the Trending AI Robots section to see which strategies are gaining momentum now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SPRY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SPRY turned positive on August 07, 2026. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SPRY's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on SPRY as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SPRY entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (48.309) is normal, around the industry mean (20.281). SPRY's P/E Ratio (151.250) is considerably higher than the industry average of (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (5.171) is also within normal values, averaging (437.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement